Value proposition

Customized phage therapies to eradicate harmful bacteria in chronic diseases

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Microbiome, Biotechnology, Drug Discovery, Phage Therapies, and Pharma